Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Capecitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | ADK | P55263 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | HBB | P68871 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.35 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Capecitabine SCHEMBL12029777 | 1.00 | LMNA (1.00) | LMNAADKTSHRMAPTPMP22 | |
| Capecitabine SCHEMBL231286 | 1.00 | LMNA (1.00) | LMNAADKTSHRMAPTPMP22 | |
| Capecitabine SCHEMBL2184820 | 1.00 | LMNA (1.00) | LMNAADKTSHRMAPTPMP22 | |
| Capecitabine SCHEMBL10013531 | 1.00 | LMNA (1.00) | LMNAADKTSHRMAPTPMP22 | |
| Capecitabine SCHEMBL21152105 | 1.00 | LMNA (1.00) | LMNAADKTSHRMAPTPMP22 | |
| Capecitabine SCHEMBL236850 | 1.00 | LMNA (1.00) | LMNAADKTSHRMAPTPMP22 | |
| Capecitabine SCHEMBL12302025 | 1.00 | LMNA (1.00) | LMNAADKTSHRMAPTPMP22 | |
| Capecitabine SCHEMBL2470888 | 1.00 | LMNA (1.00) | LMNAADKTSHRMAPTPMP22 | |
| Capecitabine SCHEMBL12948190 | 1.00 | LMNA (1.00) | LMNAADKTSHRMAPTPMP22 | |
| Capecitabine SCHEMBL12301996 | 1.00 | LMNA (1.00) | LMNAADKTSHRMAPTPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069687-A1 | THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | ASTELLAS PHARMA INC (JP) | 2026-03-12 | — | — | US | disclosed |
| EP-4689657-A1 | METHODS FOR PREDICTING AND IMPROVING THERAPEUTIC EFFICACY OF CANCER TREATMENTS AND METHODS FOR CANCER PROGNOSIS | Università Degli Studi Di Verona (IT) | 2026-02-11 | — | — | EP | disclosed |
| EP-4612329-A1 | TOXICITY MARKER FOR 5-FLUOROURACIL | Oxford University Innovation Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| EP-3738611-B1 | DIAGNOSIS AND THERAPY OF CANCER INVOLVING CANCER STEM CELLS | BioNTech SE (DE) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025121445-A1 | COMBINATION THERAPY INVOLVING BISPECIFIC BINDING AGENTS BINDING TO CLDN18.2 AND CD3 AND AGENTS STABILIZING OR INCREASING EXPRESSION OF CLDN18.2 | ASTELLAS PHARMA INC. (JP) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025120866-A1 | COMBINATION THERAPY INVOLVING BISPECIFIC BINDING AGENTS BINDING TO CLDN18.2 AND CD3 AND AGENTS STABILIZING OR INCREASING EXPRESSION OF CLDN18.2 | ASTELLAS PHARMA INC. (JP) | 2025-06-12 | — | — | WO | disclosed |
| EP-4556070-A2 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | Astellas Pharma, Inc. (JP) | 2025-05-21 | — | — | EP | disclosed |
| EP-4556071-A2 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | Astellas Pharma, Inc. (JP) | 2025-05-21 | — | — | EP | disclosed |
| US-12188097-B2 | Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis | ASTELLAS PHARMA INC. (JP) | 2025-01-07 | — | — | US | disclosed |
| CN-119177284-A | Methods and compositions for predicting therapeutic efficacy of cancer treatment and prognosis of cancer | 安斯泰来制药股份有限公司 | 2024-12-24 | — | — | CN | disclosed |
| US-20140073779-A9 | CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2014-03-13 | — | — | US | disclosed |
| US-20140073779-A9 | CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2014-03-13 | — | — | US | disclosed |
| US-20130184455-A1 | CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20130184455-A1 | CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| WO-2010039560-A2 | ACTIVE AGENT LOADED UNIFORM, RIGID, SPHERICAL, NANOPOROUS CALCIUM PHOSPHATE PARTICLES AND METHODS OF MAKING AND USING THE SAME | LABORATORY SKIN CARE, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20090042187-A1 | COMPOSITIONS AND METHODS FOR PREDICTING OUTCOME OF TREATMENT | DAKO DENMARK APS (DK) | 2009-02-12 | — | — | US | disclosed |
| US-20080241068-A1 | SYSTEM AND METHODS FOR IDENTIFYING INDIVIDUALS AT RISK FOR SYSTEMIC FLUOROPYRIMIDINE TOXICITY | COHEN JAMES M | 2008-10-02 | — | — | US | disclosed |
| US-20080004237-A1 | Polysacchocride prodrug of 5-fluorouracil (5-FU) with enhanced target specificity for galectin-3 expressing cancers | TAM JOEMY C | 2008-01-03 | — | — | US | disclosed |
| US-20070122481-A1 | Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer | ELAN CORPORATION PLC (IE) | 2007-05-31 | — | — | US | disclosed |
| US-20070122481-A1 | Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer | ELAN CORPORATION PLC (IE) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004237-A1 | Polysacchocride prodrug of 5-fluorouracil (5-FU) with enhanced target specificity for galectin-3 expressing cancers | LGALS3, LGALS3BP, LGALS1 | LMNA 3103/4885ADK 2812/4885TSHR 1482/4885 |
| US-12188097-B2 | Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis | TP53, MKI67, TSG101 | LMNA 2513/4885ADK 4428/4885TSHR 4398/4885 |
| US-20090042187-A1 | COMPOSITIONS AND METHODS FOR PREDICTING OUTCOME OF TREATMENT | TP53, CD74, TSG101 | LMNA 1592/4885ADK 4805/4885TSHR 4038/4885 |
| US-20260069687-A1 | THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | EPCAM, VSIG8, ICAM1 | LMNA 1400/4885ADK 4367/4885TSHR 443/4885 |
| US-20070122481-A1 | Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer | DPYD, TYMP, FOLR1 | LMNA 1965/4885ADK 2633/4885TSHR 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.